PBEvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with PBE, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
PBE performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/10/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | PBE ETF 2 | -0.70%– | +12.83%– | +14.59%– | +35.63%– | +57.51%– | +23.66%– |
| Flows | PBE ETF 2 | +$44M– | +$117M– | +$114M– | +$113M– | +$62M– | +$64M– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | PBE ETF 2 | +19.58%– | +19.33%– | +20.48%– | +22.57%– |
| Max drawdown | PBE ETF 2 | -5.73%– | -11.70%– | -22.21%– | -33.32%– |
| Max drawdown duration | PBE ETF 2 | 7d– | 166d– | 324d– | 1509d– |
Trading data
PBE | ETF 2 | |
Last sale 9/11/2026 at 1:30 PM | $92.91 | – |
| Previous close 09/10/2026 | $93.03 | – |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
PBE | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
PBE | ETF 2 | |
|---|---|---|
| Last price | $92.91 | – |
| 1D performance | -0.13% | – |
| AuM | $405.87 M | – |
| E/R | 0.59% | – |
Characteristics
PBE | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | Invesco | – |
| Benchmark | Dynamic Biotech & Genome Intellidex Index | – |
| N° of holdings | 30 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 23, 2005 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
PBE
USA
97.13%
Other
2.87%
ETF 2
Sectors
PBE
Healthcare
100%
Other
0%
ETF 2
Advertisement
Diversification
PBE
Total weight of top 15 holdings out of 15
61.32%
ETF 2
–
Top 15 holdings
Data as of July 31, 2026
PBE
Amgen, Inc.
5.16%
Vertex Pharmaceuticals, Inc.
4.96%
Royalty Pharma Plc
4.91%
Regeneron Pharmaceuticals, Inc.
4.90%
Biogen, Inc.
4.85%
Gilead Sciences, Inc.
4.44%
Alnylam Pharmaceuticals, Inc.
4.34%
United Therapeutics Corp.
4.06%
CareDx, Inc.
4.01%
Bio-Techne Corp.
3.66%
Illumina, Inc.
3.27%
Vericel Corp.
3.25%
Protagonist Therapeutics, Inc.
3.24%
Incyte Corp.
3.19%
Veracyte, Inc.
3.07%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
